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A  CALL  FOR  AN  INTERNATIONAL  GOVERNANCE
FRAMEWORK  FOR  HUMAN  GERMLINE
GENE EDITING
Melanie Hess*
INTRODUCTION
From December 1 to 3, 2015, the First International Summit on Human
Gene Editing took place in Washington, D.C. to “discuss the scientific, ethi-
cal, and governance issues associated with human gene-editing research.”1
Following the 2015 summit, the National Academy of Sciences (NAS) issued
the 2017 Report on Human Genome Editing: Science, Ethics, and Govern-
ance.  The report recognized that risks involved in the field of human gen-
ome editing required the addition of new principles and guidance to
existing norms, which include the protection of human dignity, “the need for
research having scientific and social value,” and the related need to generate
knowledge that promotes human health.2  To support the endeavor respon-
sibly, the report has a chapter dedicated to the state of regulatory and inter-
national oversight of the field.3  Notably, the report identified “transnational
cooperation” as critical to developing governance in the field, and stresses
the “commitment to collaborative approaches to research and governance
while respecting different cultural contexts.”4
To build on relevant discoveries and research as well as continue the
international societal dialogue about gene editing, the Second International
Summit on Human Genome Editing convened from November 27 to 29,
* Candidate for Juris Doctor, Notre Dame Law School, 2020; Bachelor of Arts,
University of California, Berkeley, 2015.  I would like to thank Professor O. Carter Snead
for his guidance, feedback, and mentorship.
1 International Summit on Human Gene Editing, NAT’L ACADS. SCI., ENGINEERING & MED.,
http://nationalacademies.org/gene-editing/Gene-Edit-Summit/ (last visited Feb, 8,
2020).
2 NAT’L ACADS. OF SCI., ENG’G & MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, AND
GOVERNANCE 31 (2017) [hereinafter 2017 NAS REPORT] (quoting COUNCIL FOR INT’L ORGS.
OF MED. SCIS. & WORLD HEALTH ORG., INTERNATIONAL ETHICAL GUIDELINES FOR HEALTH-
RELATED RESEARCH INVOLVING HUMANS 123 (2016), https://cioms.ch/wp-content/
uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf).
3 Id. at 34.
4 Id.
1369
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2018.5  During the 2018 summit, varying perspectives emerged surrounding
the advisability and ethical implications of moving forward with germline
gene editing.  Germline gene editing, the topic central to this Note, is the
editing of heritable genes that will impact future generations, and as will be
discussed, is considered a particularly problematic application of gene edit-
ing.  One commentator cautiously observed that:
[M]any of the arguments made against germline genome editing, such as
consideration of the autonomy of a child, societal equity, and possible mis-
use, can be applied as well to other medical technologies, but many jurisdic-
tions have nevertheless permitted those technologies to move forward, so
long as they are sufficiently beneficial, safe, and effective.6
More skeptical experts noted that germline editing “could be morally
permissible in certain circumstances but those circumstances do not yet exist
anywhere in the world.”7
The 2018 summit was heavily impacted by news of Chinese doctor He
Jiankui’s research, which leaked just before the summit and then was
presented at the summit, that he had created the world’s first gene-edited
human babies through the use of CRISPR-Cas9 (CRISPR) technology.8  The
reaction to this announcement was swift condemnation from the global com-
munity, given the undeveloped stage of the technology, regulation, and lack
of consensus regarding the implicated ethical issues.9  David Baltimore of the
California Institute of Technology, the chair of the 2018 Summit Organizing
Committee, described the occurrence of Dr. He’s experiment “a failure of
self-regulation by the scientific community.”10
The failure of this self-regulation is perhaps a consequence of the fact
that there is not currently a stronger international regulatory framework or
set of principles guiding this subject.  There is scant consensus on how to
regulate and what to allow, and this is largely because despite the potential
5 Second International Summit on Human Genome Editing: Continuing the Global Discussion:
Proceedings of a Workshop—In Brief, 2019 NAT’L ACADS. SCI., ENGINEERING & MED. 1 [herein-
after Proceedings of a Workshop—In Brief].
6 Id. at 6.  This perspective (paraphrased by the source) is attributed to Guido de
Wert of Maastricht University. Id.
7 Id.  This perspective (also paraphrased by the source) is attributed to Peter Mills of
the Nuffield Council on Bioethics. Id.
8 See Julia Belluz, Is the CRISPR Baby Controversy the Start of a Terrifying New Chapter in
Gene Editing?, VOX, https://www.vox.com/science-and-health/2018/11/30/18119589/
crispr-gene-editing-he-jiankui (last updated Jan. 22, 2019) (“The stated objective of He’s
experiment was to disable a gene called CCR5 so the girls might be resistant to potential
infection with HIV/AIDS.”).  A Chinese investigation into Dr. He’s experiment found that
he had in fact edited the germline of embryos, implanted them in a woman’s uterus, and
brought them to term, resulting in legal and ethical violations. See Austin Ramzy & Sui-Lee
Wee, Scientist Who Edited Babies’ Genes Is Likely to Face Charges in China, N.Y. TIMES (Jan. 21,
2019), https://www.nytimes.com/2019/01/21/world/asia/china-gene-editing-babies-he-
jiankui.html?module=inline.
9 Proceedings of a Workshop—In Brief, supra note 5, at 2–3.
10 Id. at 3.
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benefits of germline editing, the field is rife with controversy surrounding the
“safety concerns, unprecedented informed consent, challenges to human
dignity, and the potential for permanent negative impact on future genera-
tions, including its abuse for eugenics or enhancement (the parental pursuit
of specific traits for non-medical reasons).”11  There is, however, a general
consensus that no clinical applications should proceed until there is “broad
societal consensus” involving the opinions of all social groups, perhaps on a
global scale.12
This Note will argue that human germline editing ought to be subject to
a worldwide regulatory initiative contained in an international governance
framework.  It will touch on the justifications for the call for this agreed upon
framework and discuss the current state of regulation of human germline
editing, including norms and principles promulgated by international instru-
ments and important statements on the topic.  Finally, it will propose sugges-
tions for the substance that an international governance framework should
include and acknowledge the challenges in implementing such a framework.
I. WHAT IS GERMLINE EDITING?
A. Gene Editing
Gene editing, or genome editing,13 is a form of genetic engineering that
allows scientists to modify genes, thereby changing an organism’s DNA.
11 Motoko Araki & Tetsuya Ishii, International Regulatory Landscape and Integration of
Corrective Genome Editing into In Vitro Fertilization, 12 REPROD. BIOLOGY & ENDOCRINOLOGY 1
(2014) (footnotes omitted) (first citing Paul R. Billings et al., Human Germline Gene Modifi-
cation: A Dissent, 353 LANCET 1873, 1873–75 (1999); MARK S. FRANKEL & AUDREY R. CHAP-
MAN, AM. ASS’N FOR THE ADVANCEMENT OF SCI., HUMAN INHERITABLE GENETIC
MODIFICATIONS: ASSESSING SCIENTIFIC, ETHICAL, RELIGIOUS, AND POLICY ISSUES (2000); Ber-
nard D. Davis, Germ-Line Therapy: Evolutionary and Moral Considerations, 3 HUM. GENE THER-
APY 361, 361–63 (1992); James V. Neel, Germ-Line Gene Therapy: Another View, 4 HUM. GENE
THERAPY 127, 127–28 (1993); then citing Billings et al., supra; FRANKEL & CHAPMAN, supra;
then citing JOHNATHAN GLOVER, WHAT SORT OF PEOPLE SHOULD THERE BE? 45–47 (1984);
and then citing FRANKEL & CHAPMAN, supra; Davis, supra; C.S. LEWIS, THE ABOLITION OF
MAN  69–71 (1965); PAUL RAMSEY, FABRICATED MAN: THE ETHICS OF GENETIC CONTROL
(1970); Michal J. Sandel, The Case Against Perfect, ATLANTIC, April 2004, at 51–62).
12 E.g., 2017 NAS REPORT, supra note 2, at 132; Eric Lander et al., Adopt a Moratorium
on Heritable Genome Editing, 567 NATURE 165, 166 (2019) [hereinafter 2019 Call for Morato-
rium]; Press Release, Nat’l Acad. of Sci., Engineering, & Med., On Human Gene Editing:
International Summit Statement (Dec. 3, 2015), http://www8.nationalacademies.org/
onpinews/newsitem.aspx?RecordID=12032015a [hereinafter 2015 Call for a Moratorium];
see also Herve´ Chneiweiss et al., Fostering Responsible Research with Genome Editing Technologies:
A European Perspective, 26 TRANSGENIC RES. 709, 712 (2017).
13 The terms “gene” and “genome” have distinct meanings: “The term ‘genome’ gen-
erally refers to the entire sequence of DNA of an organism.  The genome includes genes:
sequences of DNA with specific functions that are involved in the production of the pro-
teins needed to carry out many biological roles.” Genome Editing in Brief: What, Why, and
How?, NUFFIELD COUNCIL ON BIOETHICS (Sept. 30, 2016), https://www.nuffieldbioethics.
org/publications/genome-editing-an-ethical-review/guide-to-the-report/genome-editing-
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Gene editing itself is not a new concept or technology: the first successful
gene editing technique was created in 1972 by scientists who discovered how
to recombine pieces of DNA to create hybrid sequences.14  This technique,
called recombinant DNA, formed the basis of gene therapy, an experimental
treatment that attempts to alleviate or cure diseases by inserting healthy
genes into DNA sequences to compensate for problematic ones.15  Gene
therapy as a treatment is currently being researched and developed in
clinical trials worldwide, and in certain situations is available for patients
seeking clinical treatments.16
Despite progress, the recombinant DNA technique was not always consis-
tent or reliable, and could be described as “more of a patch kit than a repair
shop.”17  Thus, the advent of CRISPR as a gene-editing tool in 2012 promised
to be a game changer for gene editing because of its efficiency and precision
in altering, deleting, and adding bits of DNA in living organisms.18  The pro-
tein Cas9 works like “a pair of molecular scissors, capable of cutting strands
of DNA” to remove a desired portion of the strand and replace it with a
strand that is either healthy or altered in some way.19
CRISPR promises to fulfill many different purposes, ranging from food
and agricultural applications to human gene editing.  With regard to the lat-
ter, laboratory and animal studies have demonstrated CRISPR’s potential to
correct genetic defects, similar to current applications of gene therapies.20
Another potential application is to use CRISPR to make gene drives.21  For
contextual purposes, an important distinction must be made between gene
therapies, which involve somatic cell gene editing, and gene drives, which
involve germline editing.  Somatic cells are live but nonreproductive cells
in-brief-what-why-and-how.  For purposes of this Note, the terms “genome editing” and
“gene editing” will be used interchangeably to refer to genetic modification through edit-
ing technology, such as CRISPR-Cas9.
14 Ariel Bleicher, Genome Editing Before CRISPR: A Brief History, MEDIUM (Oct. 23, 2018),
https://medium.com/ucsf-magazine/genome-editing-before-crispr-a-brief-history-f02c1e
3e2344.
15 Nat’l Insts. of Health, What Is Gene Therapy?, GENETICS HOME REFERENCE, https://
ghr.nlm.nih.gov/primer/therapy/genetherapy (last visited Feb. 9, 2020).
16 Bleicher, supra note 14.
17 Id.
18 See generally Matthew C. Nisbet, The Gene-Editing Conversation, AM. SCIENTIST,
Jan.–Feb. 2018, at 15.  For an explanation on how the CRISPR-Cas9 system works, see Nat’l
Insts. of Health, What Are Genome Editing and CRISPR-Cas9?, GENETICS HOME REFERENCE,
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting (last visited Feb. 9,
2020).  In basic terms, researchers create a small piece of RNA as a “guide” sequence,
attached to the enzyme Cas9, which is designed to target a specific sequence of DNA in the
genome.  The RNA “guide” recognizes the sequence and the enzyme cuts the DNA at that
specified point, at which point researchers can use the cell’s repair mechanisms to add or
delete parts of the genetic material, or even insert customized DNA. Id.
19 Aparna Vidyasagar, What Is CRISPR?, LIVE SCI. (Apr. 21, 2018), https://www.live
science.com/58790-crispr-explained.html.
20 See id.
21 See id.
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that inform the genetics of a single individual organism.  Somatic cell editing
would address a genetic problem affecting only that individual.22  As will be
described in Part III, clinical trials and applications of somatic cell editing
have existed in the United States since the 1980s with extensive oversight
from regulatory bodies.23  According to a recent report, over 2600 clinical
trials of gene therapies have been approved, in progress, or completed in 38
countries to date.24
Germline editing, on the other hand, is the editing of cells which are
heritable; thus, the modification made in a germline gene will be inherited
by successive generations.  Gene drives are an application of germline editing
that bias inheritance of a gene in future generations by editing heritable
germline cells.  As will be briefly discussed in the following Section, research
has been conducted on nonhuman applications of gene drives, such as engi-
neering malaria-carrying mosquitos to pass on genes that result in predomi-
nantly male offspring, thereby reducing the population, but even this
research has not yet resulted in widespread testing.25  Until Dr. He’s experi-
ment, research on human germline editing had been limited to petri dishes
or banned, either effectively or directly, in all instances.26  Furthermore, the
summits of 2015 and 2018 both resulted in calls for moratoriums on research
involving clinical applications (i.e., where a modified embryo was used to
establish a pregnancy) until certain criteria are met.27  In research and dis-
cussions of ethics, the two applications—somatic and germline—are viewed
very differently: somatic cell editing, which generally involve gene therapies,
broadly has the support of the global scientific and policymaker communities
and is on the forefront of medicine.28  Such applications of gene editing do
not pose the same controversies as germline editing, largely because they
involve individuals who are already sick, will affect only that consenting
patient, and have been more extensively researched.  In contrast, there is a
general consensus that clinical applications of human germline editing should
22 See Somatic Cell Genome Editing, NAT’L CTR. FOR ADVANCING TRANSLATIONAL SCI.,
https://ncats.nih.gov/somatic (last updated Oct. 1, 2019).
23 See infra Part III.
24 Samantha L. Ginn et al., Gene Therapy Clinical Trials Worldwide to 2017: An Update, J.
GENE MED., May 2018, at e3015, e3015 (2018).
25 Ace North, Reducing Numbers of Malaria-Transmitting Mosquitoes Using Gene Drive Tech-
nology: A Modelling Approach, BIOMED CENT. (Mar. 29, 2019), https://blogs.biomedcentral.
com/on-biology/2019/03/29/reducing-numbers-malaria-transmitting-mosquitoes-using-
gene-drive-technology-modelling-approach/.
26 See Mary Todd Bergman, Perspectives on Gene Editing, HARV. GAZETTE (Jan. 9, 2019),
https://news.harvard.edu/gazette/story/2019/01/perspectives-on-gene-editing/ (discuss-
ing Dr. He’s experiment, the resulting outcry, and general restrictions that have been
placed on human germline editing).
27 See 2019 Call for Moratorium, supra note 12; 2015 Call for Moratorium, supra note
12.
28 See Bergman, supra note 26.
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be “off limits” for now.29  While somatic gene editing and gene therapies are
not central to this Note, they are relevant where their governing regulatory
regimes overlap or provide guidance for discussions of the regulation around
germline editing.
B. General Applications of Gene Drives and Germline Gene Editing
Gene editing currently occupies a unique space in international head-
lines, with fears of dystopian worlds ruled by “designer bab[ies]” on the hori-
zon, hopes for the promise of eradication of terrible genetic diseases and
disorders, and confusion about how best to proceed with research and
clinical applications.30  However, while the discussion looms large on the
topic of human germline editing, nonhuman applications have been in aca-
demic, scientific, and policy-based discussions for many years, particularly
around the use of gene drives to engineer solutions to environmental and
agricultural problems.
A gene drive, which is an application of germline editing, is a method of
biasing the likelihood that a certain gene or trait will be inherited by a future
generation.31  Applications of gene drives have thus far been discussed seri-
ously in the context of altering populations of plant and animal species, such
as “reprogramming mosquito genomes to eliminate malaria, reversing the
development of pesticide and herbicide resistance, and locally eradicating
invasive species.”32  One of the most common uses discussed is that of eradi-
cating the mosquito that carries malaria, a venture currently being tackled by
Target Malaria, a research consortium largely funded by the Bill and Melinda
Gates Foundation, which hopes to begin field testing of CRISPR-edited mos-
quitos as early as 2024.33  It would be naı¨ve to emphasize the benefits and
promise of gene drives without acknowledging the risks: attempting to alter
wild populations could have unintended consequences that could inevitably
affect the global commons.  In fact, one of the advocates and developers of
CRISPR who touted its potential for conservation against invasive species
later cautioned that this “inclusion [as a potential benefit] was a mistake:
such drive systems lack control mechanisms and are consequently highly
invasive.”34  The theoretical and actual perils of being able to engineer and
carry out an extinction or permanent alteration of a species require little
29 Katie Hasson & Marcy Darnovsky, Gene-Edited Babies: No One Has the Moral Warrant to
Go It Alone, GUARDIAN (Nov. 27, 2018), https://www.theguardian.com/science/2018/nov/
27/gene-edited-babies-no-one-has-moral-warrant-go-it-alone.
30 See, e.g., Bergman, supra note 26.
31 See Bruce R. Conklin, On the Road to a Gene Drive in Mammals, 566 NATURE 43, 43–44
(2019).
32 Kenneth A. Oye et al., Regulating Gene Drives, 345 SCIENCE 626, 626 (2014).
33 Megan Molteni, Here’s the Plan to End Malaria with Crispr-Edited Mosquitoes, WIRED
(Sept. 24, 2018), https://www.wired.com/story/heres-the-plan-to-end-malaria-with-crispr-
edited-mosquitoes/.
34 Kevin M. Esvelt & Neil J. Gemmell, Conservation Demands Safe Gene Drive, PLOS BIOL-
OGY, Nov. 16, 2017, at e20003850.
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elaboration.  An article in The Economist ominously titled Extinction on Demand
summed up the problem of unintended and irreversible consequences: “If
drives are engineered into species that play a pivotal but previously unap-
preciated ecological role, or if they spread from a species of little ecological
consequence to a close relative that matters more, they could have damaging
and perhaps irreversible effects on ecosystems.”35
Looking at the potential risks and ethical concerns implicated in the
alteration of populations of mosquitos and plants reflects the fact that similar
applications in humans merit even closer scrutiny.  Interestingly, a 2014 arti-
cle that advocated for more thoughtful regulation of gene drives largely
wrote off the risk of altering the human population as a serious risk posed by
gene drives.  The authors reasoned that gene drives could not effectively alter
the human population because of the human species’ long generation times
and lack of effective gene editing technologies for humans.36  Much has
changed since the writing of the article.  For one, the technological capabili-
ties for human germline editing do exist now.  Furthermore, while the
authors of the article may be correct to note that gene drives will hardly have
the impact in terms of the scale and speed that they might have on mosquito
populations, this is not the exclusive, or even central, focus of the conversa-
tion around human germline editing.  There are many dangers and
unknown issues associated with altering heritable genes that will be passed on
to future generations, including ethical issues, which are arguably unique to
humans.
C. Potential Benefits of Human Germline Editing
CRISPR pioneer Feng Zhang explained the importance of a moratorium
on clinical applications and trials of human germline gene editing following
the 2018 summit, saying, “Society needs to figure out if we all want to do this,
if this is good for society, and that takes time.”37  The question of whether
human germline editing is a good thing has yet to be resolved.  However,
while the risks and ethical mores of germline editing are central to the need
for its regulation,38 there are also legitimate reasons that human germline
editing is being seriously explored: its enormous potential for good.
Germline editing could eliminate genes that cause disease, which could
positively affect the treatment of illnesses.  Somatic gene editing has proven
its potential to be a tool for disease treatment and prevention: in 2015, gene
therapies were already being used to treat eye disease, and further trials
demonstrate that this type of gene editing may be effective in treating certain
35 The Promise and Peril of Gene Drives, ECONOMIST (Nov. 8, 2018), https://
www.economist.com/briefing/2018/11/08/the-promise-and-peril-of-gene-drives.
36 See Oye et al., supra note 32, at 627.
37 Bergman, supra note 26.
38 See infra Sections II.B–C.
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blood disorders.39  With regard to germline editing, screening embryos and
using in vitro fertilization is an existing method of avoiding genetically inher-
ited diseases like Huntington’s.  However, germline editing could potentially
completely eliminate these diseases and allow couples who would otherwise
fear passing these characteristics to their offspring to parent children geneti-
cally related to them.40
II. WHY HUMAN GERMLINE EDITING NEEDS A WORLDWIDE
REGULATORY INITIATIVE
A. The Global Impact on the Human Species
Human germline editing is “an issue that will ultimately affect the entire
species.”41  There are multiple ethical objections to the clinical applications
of human germline editing, and indeed, to the research itself.  But the rea-
son these issues need to be tackled on a global scale, rather than on an indi-
vidual state level, is the fact that “[w]hile each nation ultimately has the
authority to regulate activities under its jurisdiction, the human genome is
shared among all nations.”42  Altering the human species transcends geopo-
litical borders and is not a localized issue.
Furthermore, the consequences and effects of germline editing applica-
tions would not and cannot be confined to any one state or region.  Move-
ment of persons across borders, family formation, and other human
migratory patterns guarantee that genetically modified persons and succes-
sive generations will end up dispersed across state borders.  In fact, there are
already millions of patients who cross borders for the purpose of seeking
medical treatment outside their home country or country of residence, moti-
vated by cost benefits or access to better technology.43  Absent a harmonized
set of rules for germline editing, “medical tourism” will inevitably result in
persons seeking such procedures to obtain them abroad even if it is not avail-
able in their home country.  Medical tourism was the cause a relevant high-
profile case in the European Court of Human Rights (ECHR) brought by the
Mennessons, a French family.44  Seeking to get around French laws that
banned surrogacy, the Mennessons engaged in a surrogacy arrangement in
California, where surrogacy is legal.  France refused to recognize the parent-
age of the Mennessons over their twin girls because of the illegality of the
39 Karen Weintraub, 5 Reasons Gene Editing Is Both Terrific and Terrifying, NAT’L GEO-
GRAPHIC (Dec. 3, 2015), https://news.nationalgeographic.com/2015/12/151203-gene-
editing-terrific-terrifying-science/.
40 Id.
41 2019 Call for Moratorium, supra note 12, at 166.
42 2015 Call for Moratorium, supra note 12.
43 See generally Edward Kelley, Medical Tourism, Presentation at the Global Health His-
tories Seminar 73 (Oct. 2, 2013).
44 See Press Release, European Court of Human Rights, Totally Prohibiting the Estab-
lishment of a Relationship Between a Father and His Biological Children Born Following
Surrogacy Arrangements Abroad Was in Breach of the Convention (June 26, 2014).
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arrangement.  However, the ECHR intervened because despite the legitimate
public policy justifications of France’s surrogacy laws, refusing to recognize
the legal relationship between the resulting children and their parents vio-
lated the children’s right to a social identity and possibly implicated other
issues such as their citizenship rights.45
Mennesson v. France illustrates the issues involved in failing to achieve an
international regulatory framework, made particularly problematic where the
main parties involved—the resulting children—are completely innocent of
the decision made.  The issue of international surrogacy tends to demon-
strate that where states are not aligned on procedures that will implicate
human rights, medical tourism presents ample opportunity for abuse and
confusion.46
The implications that this type of clinical application could have on the
entire human species, the medical risks, and the moral, societal, and ethical
issues associated, are shared by all of humankind, regardless of state bounda-
ries and borders.  Furthermore, there is an international interest in ensuring
that human rights and human dignity are addressed on an international
field.
B. Risks Involved in Germline Gene Editing
Legal professor and bioethicist Katherine Drabiak describes the rhetoric
around gene editing “intentionally misleading,” stating that the current state
of technology is not as efficient as it is believed to be in terms of its potential
benefits, and that, in fact, there is significant risk involved.47  The medical
risks associated with germline gene editing include mosaicism, meaning
some genes contain the intended modification and others do not.  This can
lead to serious health risks in later stages of development48 and other off-
target effects.  Off-target effects “refer to a range of unintended outcomes”
that can have serious health impacts on the child, including advanced aging
or the development of tumors.49  Problematically, preimplantation genetic
diagnosis (PGD), a process used to test the health of an embryo prior to
implantation for pregnancy,50 often fails to accurately assess the effects of
gene editing on an embryo.  The inability to use PGD to test the health of an
edited embryo would make it difficult to ascertain the germline editing pro-
cedure’s effectiveness prior to the embryo’s implantation.  In other words,
PGD cannot be used as a safeguard to indicate whether the editing has
45 Id.
46 For further discussion on the lessons learned from lack of uniform regulation on
the issue of international surrogacy, see Seema Mohapatra, Adopting an International Con-
vention on Surrogacy—A Lesson from Intercountry Adoption, 13 LOY. U. CHI. INT’L L. REV. 25
(2015).
47 Katherine Drabiak, Untangling the Promises of Human Genome Editing, 46 J.L. MED. &
ETHICS 991, 997 (2018).
48 Id. at 998.
49 Id.
50 See id. at 993.
\\jciprod01\productn\N\NDL\95-3\NDL309.txt unknown Seq: 10  6-MAR-20 10:49
1378 notre dame law review [vol. 95:3
worked correctly prior to implantation.51  PGD can, however, be used to
assess whether a defective gene is present in an unedited embryo, which is
why Drabiak points to this as a better alternative to germline editing.52
Finally, there are a range of unpredictable effects that may emerge at
any point in the future person’s life as a result of tampering with their initial
germline cells.  Drabiak notes that current research touting effectiveness
incorrectly presumes that, following a gene editing procedure, “embryo sur-
vival equates to health.”53  In other words, a test subject embryo’s surviving
the trial is not necessarily an indication of how the fetus will fare in the next
nine months, or the years and decades following its birth.  Some scholars
believe that “germline modification will never be safe . . . because interac-
tions between genes are highly integrated, designed to achieve stability and
balance, and manipulation of one location risks disrupting the biological
equilibrium.”54  Of course, this poses a serious obstacle to any research: with
the current expert consensus on a moratorium on any applications that
would result in a pregnancy,55 it is not possible to observe effects of germline
editing on later stages of development of a child.  Drabiak proposes that
these risks are severe enough that they easily outweigh any benefits that
germline gene editing could ever theoretically provide.56
C. Societal, Ethical, and Moral Considerations
“The ethical assessment of human germline genome editing falls,
broadly, into two categories: (1) those arising from its potential failure and
(2) those arising from its success.”57  Section II.B provided an overview of the
risks and dangers of germline editing procedures.  But it bears reiterating
that there are ethical considerations implicated in these potential failures of
germline editing: the ethical issues involved in the research and clinical
applications of a procedure that not only may pose risks and dangers on the
life of a nonconsenting individual, including downstream effects that may
not materialize until later in his or her development, but that would also
invariably impact his or her future offspring.
If these risks and dangers are removed and germline editing is an
unconditional success, however, the ethical issues do not go away.  On the
contrary, the ethical considerations become perhaps even more complex
51 See id. at 998.
52 See id. at 993.  PGD is an option that currently exists for reproductive planning that
allows doctors and parents to test embryos for genetic diseases and select embryos without
the mutations that might lead to certain diseases. Id.
53 Id. at 997.
54 Id. (citing Stuart A. Newman, CRISPR Will Never Be Good Enough to Improve People, 30
GENE WATCH 5, 6 (2017); Stuart A. Newman, The Hazards of Human Developmental Gene
Modification, 13 GENE WATCH 10, 10–12 (2000)).
55 See 2019 Call for Moratorium, supra note 12, at 166.
56 See generally Drabiak, supra note 47.
57 Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM. GENETICS
167, 169 (2017).
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because they are unprecedented and hypothetical.58  Even for therapeutic
applications (in other words, applications for curing disease), characterizing
gene editing as a “means of restoring genomic integrity” invokes undertones
of eugenics, “where individuals have a moral obligation to ‘scrub deleterious
mutations from the germline’ as part of a duty to prevent disease that threat-
ens society.”59  The most recently proposed moratorium on clinical applica-
tion of human germline genome editing, published in March 2019,
summarizes the possible societal effects of introducing successful germline
editing procedures:
Individuals with genetic differences or disabilities can experience stigmatiza-
tion and discrimination.  Parents could be put under powerful peer and
marketing pressure to enhance their children.  Children with edited DNA
could be affected psychologically in detrimental ways.  Many religious
groups and others are likely to find the idea of redesigning the fundamental
biology of humans morally troubling.  Unequal access to the technology
could increase inequality.  Genetic enhancement could even divide humans
into subspecies.
Moreover, the introduction of genetic modifications into future genera-
tions could have “permanent and possibly harmful effects on the species.60
The above passage primarily addresses the possibility that the use of
germline editing for genetic enhancement would follow if germline editing
were to become an acceptable procedure.  In terms of acceptability, many
distinguish between nontherapeutic genetic enhancement, or gene editing
to engineer particular human traits like athleticism or intellect, and thera-
peutic gene editing, which addresses debilitating or life threatening genetic
diseases.61  Marcy Darnovsky, head of the nonprofit Center for Genetics and
Society, believes that “[u]nlike curing disease, genetic enhancement would
be morally reprehensible.”62  The 1997 film Gattaca provides a cliche´, but
apt, illustration of the potential societal problems of genetic enhancement
and reflects society’s fears about eugenics and genetic interventions.  In this
dystopian not-too-distant future, parents have the option to conceive chil-
dren through the genetic selection of the best traits of their parents, and the
“in-valids”—individuals who were conceived without genetic intervention—
occupy a second-class position in society.63  Despite laws against genetic dis-
crimination, the Gattacan society found ways to relegate inferior employment
and social positions to those individuals who were deemed genetically infer-
58 Araki & Ishii, supra note 11, at 9.
59 Drabiak, supra note 47, at 993 (citing Ifeoma Ajunwa, Address at Data & Society,
Databite No. 41: On Genetic Coercion (June 11, 2015), http://opentranscripts.org/tran-
script/databite-ifeoma-ajunwa-genetic-coercion/?highlight=ifeoma%20ajunwa).
60 2019 Call for Moratorium, supra note 12, at 167.
61 See, e.g., Nisbet, supra note 18 (sharing survey findings that that eighty percent of
Americans would oppose changing genes to improve intelligence or physical traits,
whereas only sixty-five percent of Americans would oppose changing genes of unborn
babies to reduce their risk of disease).
62 Weintraub, supra note 39.
63 GATTACA (Jersey Films 1997).
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ior.64  Even the unrealized potential of such applications demonstrates the
necessity of implementing proper regulation before germline editing gets off
the ground so that it cannot be abused in these readily imaginable ways.
These concerns are related to a commonly invoked principle of the “slippery
slope,” in which concessions made to allow “acceptable” applications risk per-
mitting unacceptable applications further down the road.65
There is also the ethical dilemma about the unnaturalness of germline
editing and theologically based concerns that germline editing “amounts to
playing God.”66
Although allegations of playing God are two a penny in debates about break-
through technologies, with gene drives they do feel better-founded than
usual.  The ability to remove species by fiat—in effect, to get them to remove
themselves—is, like the prospect of making new species from scratch, a
power that goes beyond the past ambit of humankind.67
While the idea of causing extinction or making a species from scratch is
referencing nonhuman applications of germline editing, the underlying
principle—objecting to the tampering with species, including humankind—
remains the same, if not possibly even more objectionable in substance.
Even nonreligious persons have moral reservations related to this theory of
“playing God” that takes the form of objection to the unnaturalness of the
idea and how it constitutes a perceived assault on human dignity.  A Pew
Research study found that over twenty-five percent of nonreligious people
opposed gene editing of a baby, even where doing so would improve that
baby’s health, for the exact same reasons as did people who identified as
religious—“because it would be meddling with nature and cross a line that
should not be crossed.”68  Bioethicists have used the term the “yuck factor” to
describe the intuitive aversion people feel when confronted with the idea of
genetic engineering.  “The Yuck Factor likely has its origins in Kantian and
Christian philosophies of human dignity that permeate Western culture . . .
[and] emphasize that human life has a higher moral place than the rest of
the natural world.”69
Another frequently discussed issue is that of consent, not only of a future
individual child, but of future generations.  In attempting to debunk this
argument, professor and ethicist John Harris points out that “[w]e have liter-
ally no choice but to make decisions for future people without considering
64 Id.
65 See 2017 NAS REPORT, supra note 2, at 128 (“This continuum almost always starts
with converting single-gene disorders to a common, nondeleterious sequence at the most-
acceptable end, and moves toward enhancements that are unrelated to disease on the
least-acceptable end.”).
66 John Harris & Marcy Darnovsky, Pro and Con: Should Gene Editing Be Performed on
Human Embryos?, NAT’L GEOGRAPHIC (Nov. 26, 2018), https://www.nationalgeographic.
com/magazine/2016/08/human-gene-editing-pro-con-opinions/#close.
67 See The Promise and Peril of Gene Drives, supra note 35.
68 Nisbet, supra note 18.
69 Id.
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their consent.”70  But arguably there is a difference between simply allowing
our choices to indirectly affect future generations, and choosing to engage in
direct interventions in aspects that will affect the very personhood of future
generations.
D. Expert and Public Consensus That Regulation Is Needed
For a combination of all of these reasons, experts across fields with
knowledge on the subject of gene editing, and particularly germline editing,
are calling for caution.  The aforementioned CRISPR pioneer Feng Zhang of
the Broad Institute of Harvard and MIT, in supporting a moratorium, noted
that before beginning experimentation, society needs to decide if human
germline editing is even a good that should be pursued.  If that is decided, he
said, “we need to have guidelines first so that the people who do this work
can proceed in a responsible way, with the right oversight and quality con-
trols.”71  In reaction to Dr. He’s revelation at the 2018 summit, David Balti-
more, chair of the Summit Organizing Committee, called the fact of the
experiment “a failure of self-regulation by the scientific community.”72
Furthermore, following both the 2015 and 2018 summits, groups of
scientists and experts put out calls for a moratorium on clinical applications
of human germline editing until a “broad societal consensus” could be
reached and an international governance framework established.73  While
this consensus has not been reached and may in fact be far away,74 presuma-
bly there should be a governance framework ready to govern applications
prior to this consensus to ensure that society and science proceed with cau-
tion, wisdom, and oversight.  Furthermore, the development of principles
and potential regulatory regimes may in fact help different arms of society
come together in dialogue about the issue; in other words, resolving govern-
ance issues on the topic may be an important step in achieving this
consensus.
E. The Current Existence of Human Germline Editing Capabilities
Finally, the fact that germline editing capabilities are now out of the
realm of science fiction puts pressure on their effective regulation, regardless
of whether they are currently being applied in a clinical setting.  Germline
editing, genetic enhancement, and designer babies are not new topics of
debate or societal preoccupation (as evidenced by the aforementioned film
Gattaca) but the “apparent facility with which such modifications can now be
70 Harris & Darnovsky, supra note 66.
71 Bergman, supra note 26.
72 Proceedings of a Workshop—in Brief, supra note 5, at 3.
73 See supra note 12 and accompanying text; see also infra Part IV.
74 See Nisbet, supra note 18 (referencing several studies that indicate that most Ameri-
cans are either unsure about or actively oppose germline editing in most contexts).
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accomplished has made discussion of the issues more urgent.”75  CRISPR
and future gene editing technologies can now deliver edited DNA to human
embryos, which could then be implanted and develop into genetically modi-
fied children.  Some of these methods have already been applied to nonhu-
man mammals and tested on nonviable human embryos.76  As will be
discussed in Part III, the United States technically has regulatory frameworks
in place governing the application of human (and nonhuman) germline
editing.  However, these regulations were dreamed up in a day preceding the
true reality of human germline editing and in fact are primarily written to
address gene therapies.77  Such regulations, as well as a worldwide frame-
work, bear consideration and reconsideration now that this eventuality is
upon us.
III. CURRENT REGULATORY FRAMEWORK IN THE UNITED STATES
The United States does not have an explicit legal prohibition on human
germline editing.78  This is relatively unusual in the international commu-
nity, where there are official prohibitions on human germline editing in
many countries, including ones that allow human embryonic stem cell
research.79  That said, germline editing does not exactly have a clear path
forward in the current U.S. regulatory and political climate.
Current genome-editing protocols and clinical trials in the United States
do not have their own regulatory framework and have instead been
“absorbed into the preexisting U.S. regulatory framework for gene therapy,
whose overview is largely derived from gene transfer studies”80—despite the
fact that germline editing, while involving similar technologies and tech-
niques, has vastly different consequences and implications.
Research and experimentation that produced that recombinant DNA
gene editing on nonhuman subjects began in the 1970s.  In response, the
National Institute of Health (NIH) established the Recombinant DNA Advi-
sory Committee (RAC) in 1974.  The RAC was charged with overseeing the
development of an experimental program examining the risks of the recom-
binant DNA, minimizing their spread to other ecological situations, and
devising guidelines to be followed by researchers.81
In the 1980s, application of these techniques to human subjects began to
be recognized as a possibility, but aimed at somatic, rather than germline,
75 Dana Carroll & R. Alta Charo, The Social Opportunities and Challenges of Genome Edit-
ing, 16 GENOME BIOLOGY, Nov. 5, 2015, at 1, art. 242.
76 See id.
77 See infra Part III.
78 See Eileen M. Kane, Human Genome Editing: An Evolving Regulatory Climate, 57
JURIMETRICS 301, 319 (2017).
79 See Araki & Ishii, supra note 11, at 8.
80 Kane, supra note 78, at 310.
81 See Paul Berg et al., Potential Biohazards of Recombinant DNA Molecules, 71 PROC. NAT’L
ACAD. SCI. U.S. 2593, 2593 (1974).
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gene editing.82  Since that time, authorization for clinical trials for human
gene transfer face several bureaucratic obstacles and the submissions before
and approval of several agencies.  Any clinical trial requires submission of a
protocol to the RAC, an Investigational New Drug Application (IND) submit-
ted to the FDA, and institutional approvals from the local Institutional
Review Board (IRB) and the local Institutional Biosafety Committee (IBC).83
Gene therapy products require FDA approval, and while gene therapy
research has increased and progressed, as of 2017, no gene therapy product
has been approved for the U.S. market.84  Such products have, however,
been successfully introduced into the European market.85
In response to criticism of the regulatory system’s inefficiency, in 2014,
the Institute of Medicine (IOM) of the National Academies published a
report recommending that the RAC play a less-involved role in the approval
of protocols for gene therapies, given that the area was developed enough to
have established techniques.86  The NIH adopted the recommendations,
including one that the RAC play a larger oversight role only where novel tech-
nical issues were involved, and announced a streamlined review process for
gene transfer protocols in 2014.  This is where germline editing will likely
diverge under the current regulatory regime: as an emerging life science
technology, such research is likely to continue requiring the original exten-
sive oversight of the RAC.87
In 2009, the FDA approved the first ex vivo somatic genome editing
clinical trial, and in 2015, the FDA approved the first in vivo editing trial.88  A
few other genome-editing trials have been approved and conducted involving
gene-editing technology called ZFN technology.89  As of 2017, the first
human clinical trial involving CRISPR technology could be near.90  The cur-
rent regulatory framework has proven adequate for somatic cell genome edit-
ing, given its state of research and development as a field.91  While there is,
as of the writing of this Note, no separate set of regulations for germline
82 See Kane, supra note 78, at 307.
83 See id.
84 See id. at 308.
85 See id.
86 See INST. OF MED. OF THE NAT’L ACADS., OVERSIGHT AND REVIEW OF CLINICAL GENE
TRANSFER PROTOCOLS: ASSESSING THE ROLE OF THE RECOMBINANT DNA ADVISORY COMMIT-
TEE 80 (Rebecca N. Lenzi et al. eds., 2014), http://www.nationalacademies.org/hmd/
Reports/2013/Oversight-and-Review-of-Clinical-Gene-Transfer-Protocols.aspx.
87 See Kane, supra note 78, at 308 (“[T]he reservation of RAC review for protocols
involving novel technical issues will likely mean that any proposed genome-editing proto-
cols will automatically trigger public review by RAC for the foreseeable future (e.g., first
RAC approval of a CRISPR-Cas9 human genome-editing protocol).”).
88 Ex vivo editing means that the genes are removed from the body before they are
“edited.”  Contrast this with in vivo, which involves delivering the gene directly into a
human body.
89 See Kane, supra note 78, at 309.
90 The trial had been approved by the RAC but not the FDA. See Kane, supra note 78,
at 310.
91 See id. at 311.
\\jciprod01\productn\N\NDL\95-3\NDL309.txt unknown Seq: 16  6-MAR-20 10:49
1384 notre dame law review [vol. 95:3
editing, the 2017 NAS report noted with approval the robustness of the U.S.
regulatory regime.  Furthermore, “[b]ecause heritable genome editing would
involve the use of other assisted reproductive technologies, oversight of its
use would likely involve the same statutes and regulations that apply to IVF
and PGD.”92
Once the viability and effectiveness of gene-editing technologies became
clear, the question of editing the human germline arose almost immediately.
Germline editing in humans requires research on human embryos to be con-
ducted,93 and herein lies regulatory and ethical obstacles.  Two interdepen-
dent questions of propriety are raised: First, and central to the prior
discussion in Part II, is whether editing the human germline is appropriate in
the first place.  Second, and central to the policy and regulatory environment
in the United States, is how to regulate the research required for germline
editing where it involves human embryos.94
It is this second question that has had the greatest impact on advance-
ment of research in the United States.  The field is constrained by legislative
and other political reactions to the ethical issues and the policy debate
around the subject of editing or performing tests on human embryos.  These
constraints include the Dickey-Wicker amendment, which prohibits the use
of federal funds for most types of human embryo research and has been part
of federal appropriations bills since 1996.95  In 2015, Congress reacted to
first reports of genome editing in human embryos by adding a specific
amendment to the 2015 appropriations bill prohibiting the FDA from using
any federal funds to take administrative action regarding “research in which
a human embryo is intentionally created or modified to include a heritable
genetic modification.”96  In 2017, the first U.S. study on genome editing of
viable human embryos was published, and a few other experiments have
been published since then.97  Thus, there has been research on germline
editing in the United States, but this research has been privately funded.
IV. INTERNATIONAL INSTRUMENTS ON HUMAN GERMLINE EDITING
AND RELATED TOPICS
While individual countries, like the United States, may have laws and
regulations addressing research and clinical applications of gene editing, the
current state of the global dialogue on human germline editing consists of
conventions, commentaries, treaties, and other official statements.  This Part
will provide an overview of the international instruments that represent the
current state of international dialogue on the subject.  It will discuss the uni-
92 2017 NAS REPORT, supra note 2, at 131.
93 See Kane, supra note 78, at 311–12.
94 See id. at 312.
95 See id. at 313, 319 (“[The amendment] bans the use of federal funds to create
embryos for research or for research in which an embryo is destroyed or discarded.”).
96 Consolidated Appropriations Act of 2016, Pub. L. No. 114-113, § 749, 129 Stat. 2283
(2015).
97 See Kane, supra note 78, at 312–13.
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fying norms regarding germline editing in hopes of taking helpful learnings
from these instruments to make suggestions for an international governance
framework on human germline editing.
A. Oviedo Convention of 1997 (Europe)
The Convention on Human Rights and Biomedicine of 1997, more com-
monly known as the Oviedo Convention, is a treaty for the protection of
human rights in the biomedical field, and includes provisions for the protec-
tion of patient rights and biomedical research issues, including genetics and
organ transplantation.98  While the only signatories are the Council of
Europe and other European states, the Oviedo Convention represents the
first legally binding international treaty that addresses biomedicine in the
field of human rights, which notably includes genetic research and gene edit-
ing.  Like several international conventions on the topic, it bases its princi-
ples on the protection of human dignity and rights, but unlike those other
agreements, it goes beyond such broad principles by setting minimum stan-
dards with which members are required to comply.99  These minimum stan-
dards include a nondiscrimination provision on the basis of a person’s
genetic heritage100 and provide that genetic modification should only be
taken for “preventive, diagnostic or therapeutic purposes.”101  Importantly,
the Oviedo Convention includes a prohibition on germline editing, specifi-
cally disavowing gene editing that will impact a person’s descendants,102 and
prohibits the use of medically assisted procreation to choose a child’s sex.103
B. UN Universal Declaration on Human Genome and Human Rights of 1997
The United Nations (UN) Universal Declaration on the Human Gen-
ome and Human Rights of 1997 (the UN Declaration of 1997) lays out a set
of principles regarding research and other treatments involving the human
genome meant to help guide the development of further regulations, laws,
98 Convention for the Protection of Human Rights and Dignity of the Human Being
with Regard to the Application of Biology and Medicine: Convention on Human Rights
and Biomedicine, Apr. 4, 1997, E.T.S. No. 164 [hereinafter Oviedo Convention].
99 Id. art. 27 (“None of the provisions of this Convention shall be interpreted as limit-
ing or otherwise affecting the possibility for a Party to grant a wider measure of protection
with regard to the application of biology and medicine than is stipulated in this Conven-
tion.”).  The Oviedo Convention is not without criticism, however. See Human Rights in
Biomedical Field: Concern over the Oviedo Convention, CONF. EUR. CHURCHES (Oct. 16, 2018),
http://www.ceceurope.org/human-rights-in-biomedical-field-concern-over-the-oviedo-con-
vention/ (discussing calls for withdrawal of one of the Convention’s protocols for discrimi-
nating against persons with mental disorders).
100 Oviedo Convention, supra note 98, art. 11.
101 Id. art. 13.
102 See id. (“An intervention seeking to modify the human genome may only be under-
taken for preventive, diagnostic or therapeutic purposes and only if its aim is not to intro-
duce any modification in the genome of any descendants.”).
103 Id. art. 14.
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and policies at the national and international level.104  The declaration itself
does not contain developed or specific rules; rather, it references “national
law” in order to first and foremost keep all research under the oversight of
states.  For example, it states that “[r]esearch, treatment, or diagnosis affect-
ing an individual’s genome shall be undertaken only after rigorous and prior
assessment of the potential risks and benefits pertaining thereto and in accor-
dance with any other requirement of national law.”105
However, the declaration does condemn “[p]ractices which are contrary
to human dignity, such as reproductive cloning of human beings,”106 and
invites states and international organizations to “identif[y] such practices . . .
[and take] the measures necessary to ensure that the principles set out in this
Declaration are respected.”107
C. NAS International Summit on Human Gene Editing 2015 and Subsequent
NAS Report 2017
From December 1 to 3, 2015, the National Academy of Sciences held the
First International Summit on Human Gene Editing, which “convened
experts from around the world to discuss the scientific, ethical, and govern-
ance issues associated with human gene-editing research.”108  Following the
presentations, reports, and other research presented at the summit, in 2017
the Committee on Human Gene Editing published a report summarizing the
proceedings and relevant findings, and included recommendations for pro-
ceeding with research and experimentation of human genome editing.109
The report details the current state of regulatory, governance, and ethical
issues surrounding human genome editing, and endorsed the current pro-
ceedings of somatic cell genome editing in humans.  Notably, it took a mea-
sured stance with regard to germline editing, noting that “[h]eritable
germline genome-editing trials must be approached with caution, but cau-
tion does not mean they must be prohibited.”110
Importantly, this report has an entire chapter dedicated to the state of
regulatory and international oversight of the field and principles for govern-
ance.111  The report details seven general principles necessary to promote
the safe, effective, and ethical research of human genome editing.112  These
104 Universal Declaration on the Human Genome and Human Rights, Nov. 11, 1997,
UNESCO Gen. Conf., 29th Sess., endorsed by the United Nations in G.A. Res. 53/152 (Dec. 9,
1998) [hereinafter the UN Declaration of 1997].
105 Id. art. 5.
106 Id. art. 11.
107 Id.
108 International Summit on Human Gene Editing, supra note 1.
109 2017 NAS REPORT, supra note 2, at 189.
110 Id. at 134.
111 Id. at 29.
112 These principles are: (1) promoting well-being, (2) transparency, (3) due care, (4)
responsible science, (5) respect for persons, (6) fairness, and (7) transnational coopera-
tion. Id. at 33.
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principles are intended to guide the development of an emerging field of
technology and provide considerations for navigating tricky technical, ethi-
cal, legal, and policy-oriented questions.  Of note, the seventh principle is
“transnational cooperation” and stresses the “commitment to collaborative
approaches to research and governance while respecting different cultural
contexts.”113  These principles support the idea of implementing an interna-
tional governance framework.  With regard to governance, the report recom-
mends a comprehensive list of predicate conditions that must be met prior to
proceeding with germline genome editing,114 concluding that the U.S. regu-
latory system currently provides adequate oversight of genome-editing
research and can serve as a model of a regulatory regime.115
Finally, the report included the common refrain for a moratorium—a
statement from the organizers of the summit that the organizers of the 2015
summit (described further below in Section IV.D) “call[ing] for a pause of
some undefined duration in any attempt at heritable genome editing” until a
“broad societal consensus” had been reached on a global scale.116
D. The Call for a Moratorium on Clinical Application in 2015
In 2015, the organizing committee for the International Summit on
Human Gene Editing in 2015 called for a moratorium on clinical applica-
tions involving alteration of the human germline genome through gene-edit-
ing technology.117  The group declared that until there was a consensus
about the proposed application of gene-editing technologies, it would be
“irresponsible to proceed.”118  Importantly, these scientists also called for an
ongoing forum for a global dialogue of the issue:
While each nation ultimately has the authority to regulate activities under its
jurisdiction, the human genome is shared among all nations.  The interna-
tional community should strive to establish norms concerning acceptable
uses of human germline editing and to harmonize regulations, in order to
discourage unacceptable activities while advancing human health and
welfare.119
It is important to note that these scientists did not call for an absolute
moratorium on research and experimentation; in fact, they noted that
“[i]ntensive basic and preclinical research is clearly needed and should proceed,
subject to appropriate legal and ethical rules and oversight” to gain a better
113 Id. at 34.
114 See infra Section V.C.
115 See 2017 NAS REPORT, supra note 2, at 59.  For an overview of the U.S. regulatory
system for gene editing, see Kane, supra note 78, at 311–23.
116 2017 NAS REPORT, supra note 2, at 132 (quoting 2015 Call for Moratorium, supra
note 12).
117 Nicholas Wade, Scientists Seek Moratorium on Edits to Human Genome That Could Be
Inherited, N.Y. TIMES (Dec. 3, 2015), https://www.nytimes.com/2015/12/04/science/
crispr-cas9-human-genome-editing-moratorium.html.
118 2015 Call for Moratorium, supra note 12.
119 Id.
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understanding of risks, benefits, and ways forward with clinical use.120  How-
ever, this research should only proceed provided that where research results
in modified human embryos or germline cells, those modified embryos or
cells are not used to establish a pregnancy.121
E. NAS International Summit on Human Genome Editing 2018
In November 2018, the Second International Summit on Human Gen-
ome Editing was held in China, bringing together over five hundred stake-
holders including scientists, ethicists, policymakers, medical professionals,
and patient group representatives.  The purpose was to continue the discus-
sion called for by the first summit to explore risks and benefits, consider
regulatory and policy perspectives, and ethical and cultural
considerations.122
This summit raised the stakes around these discussions, of course, after
Dr.  He announced that he had used edited embryos to establish a preg-
nancy, which had resulted in twin girls.  The experiment was condemned for
violating several international and ethical norms, but notably revealed not
only the gaps in international governance around this issue,123 but also a
clear consensus that the world is not ready for such clinical applications.
F. Call for a Moratorium 2019
In response to events at the 2018 summit, on March 13, 2019, the
organizers of the summit published a renewal of the call for a moratorium on
clinical applications of human germline genome editing.124  The authors
recalled the moratorium proposed in 2015, but noted that “subsequent
events suggest that this [initial] statement was inadequate.”125  The authors
further noted that no mechanism had been created to “ensure international
dialogue about whether and, if so, when clinical germline editing might be
appropriate.”126
Interestingly, this second call proposes what is probably the most specific
and robust “international framework” to guide the development of the dis-
cussion and creation of governance for human germline gene editing that
exists today.  While the proposal does not institute specific rules or guidelines
for implementing regulation, it acknowledges and justifies this big picture
approach, stating that a “purely regulatory approach will [not] suffice,
because it cannot address many of the fundamental questions.”127  The
120 Id. (emphasis added).
121 See id.
122 Proceedings of a Workshop—in Brief, supra note 5, at 1.
123 This is reflected in the reactions to Dr. He’s experiment by experts and attendees.
See id. at 2–3.
124 2019 Call for Moratorium, supra note 12.
125 Id.
126 Id.
127 Id.
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authors also rejected an international treaty, instead favoring a voluntary
pledge by nations to not allow any clinical application of germline editing
until certain requirements are met for a system of governance and oversight.
Suggestions for these requirements include a five-year fixed-period morato-
rium while more research is collected, and the creation of an international
coordinating body.  This body could assess “broad societal consensus,” create
an international panel that serves as oversight, and provide states with com-
prehensive and objective information through issuance of periodic
reports.128
V. NECESSARY AND PROPER SUBSTANCE AND DESIGN FOR AN INTERNATIONAL
GOVERNANCE FRAMEWORK
The numerous international instruments and commentaries already in
existence repeat a few essential phrases and ideas.  First, clinical applications
of gene editing on the human germline should not proceed until there is a
“broad societal consensus” on the proposed application of the gene-editing
technology.129  Second, no clinical application should take place until risks
and benefits have been properly assessed.  These risks include medical risks
to the immediate and future descendants that would inherit an edited
human genome germline; the societal, ethical, and moral risks; and even the
risk of permanent alteration and damage to the human species.  Interest-
ingly, the commentary suggests that consensus supports the research of
germline gene editing so long as the embryos are not used to establish a
pregnancy, presenting a serious obstacle to the development of later stages of
research.130  In other words, given the unpredictable nature of the risks as
described by Drabiak—many of which may be impossible to accurately or
adequately assess without allowing gene-edited embryos to proceed into later
stages of development—it is understandable that some researchers have
asserted that germline editing “will never be safe.”131  This is supported—or
actually heightened—by the fact that germline editing is irreversible by
nature, making any “mistakes” which reveal themselves in future children
impossible to rectify.132
128 Id.
129 See Chneiweiss et al., supra note 12, at 712 (“At the present time, there must be
opposition to any demands for the modification of the related legal framework, in so far as
clinical applications are concerned . . . until consensus has been reached with multiple
partners throughout civil society.”); 2019 Call for Moratorium, supra note 12, at 167
(“[C]linical germline editing should not proceed for any application without broad socie-
tal consensus on the appropriateness of altering a fundamental aspect of humanity for a
particular purpose.”); 2015 Call for Moratorium, supra note 12 (“It would be irresponsible
to proceed with any clinical use of germline editing unless and until . . . there is broad
societal consensus about the appropriateness of the proposed application.”).
130 See 2019 Call for Moratorium, supra note 12; Drabiak, supra note 47, at 997–99.
131 Drabiak, supra note 47, at 997.
132 See id. at 998 (“That is, what is to be done with the experiments gone wrong—future
persons—who suffer health deficits arising from such germline intervention?  Despite
Steven Pinker’s dismissive guarantee ‘of course we would not create embryos with the
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Finally, these instruments call for international collaboration toward
establishing norms and a guiding framework.  The 2019 call for a morato-
rium represents one of the most robust set of suggestions for an approach
that the international community could take with regard to establishing
norms and a guiding framework for human germline editing.  Notably, there
is an express distinction made between somatic and germline editing, as well
as between research and clinical applications of germline editing.  While
clinical applications and trials of germline editing at this point are generally
considered to be unacceptable, research could responsibly proceed, accord-
ing to these experts, “provided that these studies do not involve the transfer
of an embryo to a person’s uterus.”133  These experts also noted that with
regard to international governance, a “purely regulatory approach will [not]
suffice”134 because of the narrow mandates of regulatory agencies.  The UN
Declaration of 1997 similarly puts the onus on individual states and national
law to carry out the specific aspects of implementing a set of unified interna-
tional guiding principles.135
An international governance framework must above all emphasize the
principle of human dignity, mentioned in most of the existing instruments
discussed in Part IV, as well as identify some of the most pressing controver-
sies and provide guidelines so each state can tailor their regime while main-
taining minimum standards.  However, the design of an international
governance framework, as noted by the authors of the 2019 call for a morato-
rium, should aim to give guidelines, and in some cases, set outer limits, that
then ultimately allow each state to implement the overarching norms in a
tailored manner into their own individual societies and legal systems.  Part V
will attempt to flesh out the most important elements that should be present
in an international governance framework.  It will describe the substance of
concrete commitments that could be made by the international community
so that this framework is capable of fitting different societies and evolving
with new technologies, consensus, and needs of the field.
A. Agreement to Seek Broad Societal Consensus.
Experts have emphasized that a clear consensus ought to be reached
before any clinical applications or trials of germline editing should proceed
at all.136  Broad societal consensus must involve a “wide range of voices . . .
equitably engaged from the outset,”137 but may be difficult to measure and
achieve.  In terms of incorporating a “broad societal consensus” requirement
into an international governance framework, the issue is difficult from a defi-
probability of being sick and deformed,’ one can imagine future persons injured by these
experiments would not be assuaged by these cavalier promises.”).
133 2019 Call for Moratorium, supra note 12, at 166.
134 Id. at 167.
135 UN Declaration of 1997, supra note 104.
136 See 2019 Call for Moratorium, supra note 12, at 167.
137 Id.
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nitional as well as a practical standpoint: What does a broad societal consen-
sus look like, and how is it achieved?
One of the problems with achieving consensus is that much of society
still does not know what germline gene editing is, much less how they feel
about it, inhibiting the ability to comprehend fully and then assess its
broader implications.138  Thus, a governance framework should establish
guidelines for (1) achieving societal consensus, which might include a pro-
cess for informing the public, such as through consistent reporting on multi-
ple perspectives and developments of the technology and its risks, benefits,
and ethical ramifications;139 (2) measuring of societal consensus; (3) estab-
lishing timelines for checking “approval” levels; and (4) deciding the steps to
be taken depending on the approval level.  The 2019 call for a moratorium
suggests a five-year waiting period for this dialogue to develop.140  Societal
approval may mean forging ahead, and consistent ambivalence may mean
maintaining the current holding pattern as the technology and research
develop.  A trickier question would arise if society decided it disapproved:
Does disapproval mean abandoning all efforts to investigate and implement
germline editing into medical procedures?  And finally, broad societal con-
sensus must address not only the acceptability of germline editing in the first
instance but also the line between acceptable and unacceptable applications
of human germline editing.
B. Creation of Standards Distinguishing Between Acceptable
and Unacceptable Applications
As a related part of achieving consensus, an international framework
should put forth suggestions for acceptable and unacceptable applications of
germline gene editing as a procedure.  As an initial matter, to generate this
list of applications it must be taken as given that it will one day be acceptable
to use germline editing to allow a couple to biologically conceive their own
child.  Otherwise, germline editing to prevent genetic diseases would not be
necessary; individuals that wish to become parents have a range of existing
alternatives such as PGD, adoption, or surrogacy, that would similarly prevent
those parents from passing on any congenital defects.141
138 Surveys have revealed that forty percent of Americans are “not sure” whether it is
morally acceptable or not to gene edit babies to give them a reduced risk of disease.  Nis-
bet, supra note 18.  Forty-two percent of Americans know “nothing at all” on the subject of
germline modification and only nine percent admit to knowing “a lot.” Id.
139 See id. (making a case for news organizations as an avenue for “provid[ing] the
information, frames of reference, and narratives that scientists, journalists, funders, policy
makers, and societal leaders frequently draw upon to set policy, make decisions, or com-
municate with various segments of the public who trust their advice”).
140 2019 Call for Moratorium, supra note 12, at 168.
141 See Harris & Darnovsky, supra note 66 (“It is true that a few couples—a very small
number—would not be able to produce unaffected embryos, and so could not use PGD to
prevent disease inheritance.  Should we permit germline gene editing for their sake?  If we
did, could we limit its use to cases of serious disease risk?”).
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One such distinction between acceptable and unacceptable applications
might be preventive and therapeutic versus genetic enhancement proce-
dures.  To borrow an idea from the Oviedo Convention, a governance frame-
work could allow germline editing only where it would serve a “preventive,
diagnostic or therapeutic” function with regard to a heritable genetic disease.
However, even the complexity of disease prevention must be acknowl-
edged.142  Single-gene disorders, caused by the mutation or change occur-
ring in a single DNA sequence, such as cystic fibrosis, Huntington’s disease,
and sickle cell anemia, can be fatal and seriously reduce the quality of life of
suffering individuals.143  Given that they only affect a single-gene inheri-
tance, they could also potentially be straightforward to address through
germline editing.144  There are other diseases, such as arthritis, heart disease,
and cancer, that are the result of multifactorial inheritance, meaning they
are caused by the combination of environmental factors and multiple herita-
ble traits.145  Such diseases may pose greater difficulty in editing and are less
certain to manifest, or may have alternative treatment options available if
they do.146  These line-drawing questions are inextricably linked with ethical
quandaries, including ones that are “particularly important from a disability
rights perspective.”147  “One open question is where to draw the line between
disease treatment and enhancement, and how to enforce it, considering dif-
fering attitudes toward conditions such as deafness.”148
Because societal consensus and morality, as well as technical develop-
ments in the field, are not static, it would be advisable to include a method of
determining where the line for applications should be drawn so that it can-
not be abused.  How should germline-editing applications respond to these
different diseases?  An international framework should address this question
by putting forward a flexible method, based on factors such as certainty of
manifestation, the preventative potential of a genetic treatment, and availa-
bility of existing treatments for the disease, to help answer this question.
From the outset, the absolute outer limit of acceptable applications
should be firmly established.  Part of this line drawing, or identifying a
method by which to determine where the line goes, will involve identifying
the potential problems with germline editing as a preventative measure and
as a tool for genetic enhancement, and being prepared to ask and answer
forward-thinking questions.  For example, how can we ensure that germline
editing will not exacerbate inequalities or become a tool for discrimination?
142 Oviedo Convention, supra note 98, at 4.
143 Melissa Conrad Sto¨ppler, Genetic Diseases (Disorder Definition, Types, and Examples),
MEDICINENET, https://www.medicinenet.com/genetic_disease/article.htm#what_is_a_
genetic_disease_how_is_it_defined (last visited Feb. 9, 2020).
144 See 2017 NAS REPORT, supra note 2, at 19.
145 Sto¨ppler, supra note 143.
146 For a discussion on how different genetic peculiarities affect how germline editing
might respond in treatment, see 2017 NAS REPORT, supra note 2, at 117–18.
147 Harris & Darnovsky, supra note 66.
148 Bergman, supra note 26.
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One of the ethical issues that germline editing threatens to pose is that ine-
quality will be enhanced by the creation of genetically superior humans.  If
genetic enhancement is ultimately approved of, will such offerings only be
accessible to the elite?  Will genetic enhancement be restricted to seemingly
“innocent” purposes, such as choosing eye color?  And what does innocent
mean?  Purely cosmetic?
The use of germline editing for genetic enhancement is so fraught that
at the outset, use of germline editing for genetic enhancement purposes
should be considered the outer line that should not be crossed.  Such a pro-
hibition is supported by the 2017 NAS report,149 and the 2019 call for a mor-
atorium notes that “[g]enetic enhancement of any sort would be
unjustifiable at this time.”150  This may change as technology develops, but
the debate over the balancing problem between individual freedom (for
example, to choose to use an existing germline editing procedure for genetic
enhancement purposes) and societal interests (such as the societal interest in
prohibiting such an application) may be better suited for a later date.  Such
problems have historically played out in U.S. civil rights jurisprudence and
legal decisions, “which compare the burdens on individual liberties or the
discriminatory impact of those burdens to whether there is a rational or com-
pelling need for these particular state restrictions.”151
C. Establish Preconditions for Experimentation and Clinical Trials
An international governance framework should include suggestions for
predicate conditions prior to conducting clinical trials so that research con-
ducted is appropriate to societal consensus, as well as with regard to the
safety and efficacy of the technologies.  These preconditions could be
adopted from the 2017 NAS report, which recommends a comprehensive list
of predicate conditions that should be met prior to proceeding with human
germline editing:
• the absence of reasonable alternatives;
• restriction to preventing a serious disease or condition;
• restriction to editing genes that have been convincingly demonstrated to
cause or to strongly predispose to that disease or condition;
• restriction to converting such genes to versions that are prevalent in the
population and are known to be associated with ordinary health with lit-
tle or no evidence of adverse effects;
• availability of credible preclinical and/or clinical data on risks and poten-
tial health benefits of the procedures;
• ongoing, rigorous oversight during clinical trials of the effects of the pro-
cedure on the health and safety of the research participants;
• comprehensive plans for long-term, multigenerational follow-up that still
respect personal autonomy;
• maximum transparency consistent with patient privacy;
149 2017 NAS REPORT, supra note 2, at 13.
150 2019 Call for Moratorium, supra note 12, at 166.
151 2017 NAS REPORT, supra note 2, at 119.
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• continued reassessment of both health and societal benefits and risks,
with broad ongoing participation and input by the public; and
• reliable oversight mechanisms to prevent extension to uses other than
preventing a serious disease or condition.152
Notably, some of these conditions, including the “availability of credible
preclinical and/or clinical data on risks and potential health benefits of the
procedures,”153 would be impossible to meet in today’s state of regulation
and stage of research on the subject.  Experts have further noted that morally
permissible circumstances for germline editing could potentially exist, but do
not yet in any jurisdiction.154  These predicate conditions address many of
the concerning risks that have been discussed: restriction to life-saving appli-
cation and ensuring that any benefits are strong enough to outweigh the
risks.  It goes without saying that no clinical trials or applications should pro-
ceed until the safety and efficacy of the procedures are reasonably sure.  A set
of preconditions would help to ensure that research and experimentation
proceed responsibly and within previously agreed upon boundaries.
D. Recommendation for a Regulatory Regime and Approval Process for Research
and Clinical Applications
If the time comes for clinical trials to proceed, there must be adequate
oversight over any such applications.  Thus, an international governance
framework should include a recommendation for oversight of any research
and clinical applications of human germline editing in the form of a robust
approval process by regulatory bodies.  The 2017 NAS report concludes that
the U.S. regulatory system currently provides adequate oversight of genome-
editing research, and thus could provide a starting framework to other indi-
vidual jurisdictions for germline editing.155  An international governance
framework may detail the level of regulation that should be required and
hold out robust regulatory regimes as an example for any countries that have
not yet implemented such regimes.  The recommendation could include a
note about designing regulations that restrict clinical applications but are not
so strict as to stifle discovery and research.  Many countries currently have in
place prohibitions that prevent even the research of germline editing (given
its effect on human embryos).156  But as countries begin to explore allowing
research to proceed there should be guidelines available for how to do so
responsibly.  This will allow countries to proceed with research to the level of
their comfort with regard to individual cultural, social, and scientific norms.
152 Id. at 134–35.
153 Id. at 134.
154 See Proceedings of a Workshop–in Brief, supra note 5, at 6.
155 See 2017 NAS REPORT, supra note 2, at 59.
156 See Araki & Ishii, supra note 11, at 8.
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E. Establish an International Coordinating Body
The 2019 call for a moratorium makes a crucial suggestion that will not
only help to harmonize international norms and principles about the accept-
ability of applications and achieve societal consensus, but also provide over-
sight over future dialogue, research, and applications: the creation of an
international coordinating body on human germline editing.157  This body
could assess broad societal consensus and create an international panel that
provides states with comprehensive and objective information through issu-
ance of periodic reports.158  The makeup of the body would be a diverse
group of interdisciplinary experts from multiple countries, tasked with com-
piling recommendations on best practices, reporting on progress of the tech-
nology and broader society’s dialogue, and ensuring transparency with
decisions that have a potential global impact.  Finally, this group could be
constantly reevaluating the international governance framework to identify
gaps, address unforeseen issues as they arise, and implement additional pre-
conditions as the day for widespread clinical trials approaches.  Most of all,
this group could serve as a neutral body representing a unification of global
efforts and help to prevent competitive races to the technology among differ-
ent states.  After all, “no individual or organisation—no scientist or fertility
doctor, no biotech company or fertility clinic, no advisory committee or
bioethics council or scientist-dominated summit—has the moral warrant to
skip over these minimum criteria and try to hurry things along.”159
CONCLUSION: CHALLENGES TO INTERNATIONAL GOVERNANCE FRAMEWORK
AND THE WAY FORWARD
International agreement can be difficult to achieve, and global trends of
nationalism and isolationist attitudes tend to exacerbate these difficulties.
However, even aside from this, achieving an international regulatory frame-
work on a new technology and capability poses several challenges.  For one,
the idea of broad societal consensus is touted as an important step moving
forward.  But what does a broad societal consensus look like on a global
scale?  It will be difficult enough to establish or measure consensus in one
society, and cultural and societal differences threaten to make true global
consensus next to impossible to achieve.  For example, U.S. society may
decide that it is acceptable to use germline editing to allow parents to choose
the sex of their child, but for other countries more fraught with gender ine-
qualities and historical controversy about a child’s gender, such as India and
China, such an application may pose an insurmountable ethical dilemma.
Another challenge with approaching the question is that bioethics around
medical interventions do not address human germline editing as a prevent-
ative measure.  After all, most of Western medicine involves intervening with
157 2019 Call for Moratorium, supra note 12, at 168.
158 Id.
159 Hasson & Darnovsky, supra note 29.
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nature and thus medical interventions have their own code of ethics,160 but
“[b]y definition, germline gene editing would not treat any existing person’s
medical needs.”161  This means that the ethics surrounding germline editing
may have to be developed from a point further back than many realize.
If a worldwide regulatory initiative is not possible, how should the
United States and other countries proceed?  The United States should keep
in place the existing regulatory regimes (which have been approved of by the
2017 NAS report) and begin to encourage discussions about the desirability
of human germline editing and where the line should be drawn between
acceptable and unacceptable applications.  If nations are forced to go it
alone with regard to developing norms and regulations for human germline
editing, a crucial question will be how to handle issues such as medical tour-
ism, immigration, and other consequences of a global and mobile world.
This may require looking to other areas where there is a lack of universal
consensus on topics concerning alternative reproductive technologies, and
where states and enforcement bodies have succeeded and failed, such as with
international surrogacy as illustrated in the Mennesson case.162
While the medical risks can be ascertained, it is difficult to know whether
the ethical and social fears are overblown.  After all, while germline editing
capabilities exist, they are, broadly speaking, yet untested and undeveloped.
At the same time, different countries are moving forward with germline
research, and to different extents.  While condemned by the scientific com-
munity and by the Chinese government, Dr. He is a cautionary tale for what
may happen absent adequate oversight and established norms.  In response
to Dr. He’s experiment, which may have used government funds and banned
techniques, China has proposed regulations for human gene editing.163
Other countries are not far behind allowing germline editing: in 2018, Japan
released draft guidelines that would allow gene editing in human embryos
(though they would still restrict the use of these embryos for
reproduction).164
With these developments, broader questions—for example, can society
be trusted to handle these capabilities responsibly and in a way that does not
result in a Gattaca-like dystopia?—almost appear to be moot.  Now that the
capability exists, it seems unlikely that there is any choice but to address
problems that will arise.  Dr. He’s experiment may have served as a catalyst
for the creation and implementation of regulations such as those proposed
in Japan and China, but the international community should not wait for
160 See Code of Medical Ethics Overview, AM. MED. ASS’N, https://www.ama-assn.org/deliv-
ering-care/ethics/code-medical-ethics-overview (last visited May 5, 2019).
161 Harris & Darnovsky, supra note 66.
162 See supra note 44 and accompanying text.
163 See Jef Akst, China Proposes New Gene-Editing Regulations, SCIENTIST (Feb. 27, 2019),
https://www.the-scientist.com/news-opinion/china-proposes-new-gene-editing-regula-
tions-65544.
164 David Cyranoski, Japan Set to Allow Gene Editing in Human Embryos, NATURE (Oct. 3,
2018), https://www.nature.com/articles/d41586-018-06847-7.
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another global ethical and scientific disaster to retroactively try to address the
problems posed by germline editing.  Given the global nature of the issue,
the ethical and social issues that transcend state lines, and the potential
impact on the human species, there should be an international governance
framework that helps to harmonize norms, and which prods states to develop
these norms together when it comes to human germline editing.  Proactive
development of such a framework and thoughtful engagement in dialogue
will be essential to ensuring, if society decides to move forward, that any
applications of this potentially treacherous technology will, instead of posing
bewildering and dangerous ethical and medical dilemmas, be conducted
responsibly and in a way that ultimately benefits humankind.
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